Lv2
184 积分 2022-01-04 加入
Mechanism by which the molecular glue-like verteporfin induces IRE1α dimerization and activation to synergize with AKT inhibition in breast cancer
21天前
已完结
Molecular glues evolve from serendipity to rational design
29天前
已完结
Neo‐Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein
1个月前
已完结
Synthetic and Medicinal Chemistry Perspectives on Cereblon‐Binding Molecular Glue Degraders: Recent Advances and Emerging Trends
1个月前
已完结
Discovery and Evaluation of a PROTAC Degrader Targeting SAMHD1 for the Treatment of Pulmonary Fibrosis
1个月前
已完结
Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines
2个月前
已完结
Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma
2个月前
已完结
The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition
3个月前
已完结
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
3个月前
已完结
OICR-41103 as a chemical probe for the DCAF1 WD40 domain
3个月前
已关闭
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
9个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
9个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
9个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
9个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
9个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
9个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
9个月前
已采纳
皖公网安备34019202002308
